SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
SEC Accession No. 0001193125-17-162801
Filing Date
2017-05-08
Accepted
2017-05-08 17:18:02
Documents
5
Group Members
NOVARTIS AG

Document Format Files

Seq Description Document Type Size
1 SC 13G d393443dsc13g.htm SC 13G 61056
2 EX-99.1 d393443dex991.htm EX-99.1 663
3 EX-99.2 d393443dex992.htm EX-99.2 4596
4 EX-99.3 d393443dex993.htm EX-99.3 4902
5 GRAPHIC g393443dsp11.jpg GRAPHIC 108415
  Complete submission text file 0001193125-17-162801.txt   222380
Mailing Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000
Business Address C/O NOVARTIS INTERNATIONAL AG WSJ-200.220 CH-4002 BASEL V8 0000000000 41-61-324-6210
Novartis Bioventures Ltd (Filed by) CIK: 0001297709 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: SC 13G

Mailing Address 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878
Business Address 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Subject) CIK: 0001326190 (see all company filings)

IRS No.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-80900 | Film No.: 17823458
SIC: 2834 Pharmaceutical Preparations